A first in human study of BAY 1834942.
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2018
At a glance
- Drugs BAY 1834942 (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- 11 Apr 2018 New trial record
- 05 Apr 2018 According to a Bayer media release, company is planning to start this study in 2018. Bayer is developing this drug in collaboration with German Cancer Research Center (DKFZ).